October 2010, MilleGen is invited to give a presentation at Therapeutic Antibodies Europe 2010, 13-14 October 2010, Millennium Mayfair Hotel, London, UK. Read more
August 2010, MilleGen announces the puplication of a paper entitled "Mutagen: a random mutagenesis method providing a complementary diversity generated by human error-prone DNA polymerases." in Methods Mol Biol. Read more
July 2010, MilleGen is pleased to announce the successful evaluation by the "Fonds unique Interministériel" (10 AP FUI) to fund a collaborative project with LFB Biotechnologies and UMR6239 CNRS-Université François Rabelais de Tours. Read More
June 2010, data obtained in a collaboration project between Copenhagen Univ. Stanford Univ., and MilleGen funding by Juvenile Diabetes Research Foundation (JDRF) have been presented at the 70th Scientific Sessions of American Diabetes Association, June 25 - 29, 2010, Orlando, Florida. Read more
May 2010,MilleGen is invited to give a presentation at the Norwegian/French Cancer Cluster partnering breakfast for big-pharma partnering representatives during BIO2010 in Chicago, May 4th, 2010 at Hyatt Regency Chicago on the Riverwalk, Chicago, IL, USA.
March 2010, MilleGen's key patent of molecular evolution technology (MutaGen) was granted in the United States (US7670809B2).
2009
October 2009, MilleGen will give a presentation of its antibody engineering platform at the GDR ACCTH (Anticorps et Criblage Thérapeutique) event (October 22th, 2009), Ecole Normale Supérieure, Cachan, France.
October 2009, MilleGen is invited to give a presentation at the "Cancéropôle Grand Sud Ouest" event (October 15th-16th, 2009),Limoges, France. Read more
August 2009, MilleGen announces the puplication of a paper entitled "Alternative-splicing-based bicistronic vectors for ratio-controlled protein expression and application to recombinant antibody production" in Nucleic Acids Research (constructs that allow a ratio-controlled expression of proteins of interest in stably transfected cell lines. (PMID: 19729510).
May 2009, MilleGen is invited to give a presentation at the Norwegian/French Cancer Cluster partnering breakfast for big-pharma partnering representatives during BIO2009 in Atlanta, May 19th, 2009 at Hyatt Regency, Atlanta, GA, USA.
May 2009, MilleGen is invited to give a presentation at the "Fast-Track R&D Partnering with France" event (May 18th, 2009) at Bio2009, Atlanta, GA, USA. Read more
February 2009, The French “Ministère de l'Enseignement supérieur et de la Recherche” as renewed the registration of MilleGen as an organization carrying out R&D activities. This certification allows private companies to include the research realized by MilleGen as contract services in the “crédit d’impot recherche”.
January 2009, MilleGen is invited to give a presentation of its antibody discovery platform at PepTalk 2009 - Implementing the next generation of antibodies (January 14-16, 2009), San Diego, CA, USA.
2008
October 2008, MilleGen publishes in Analytical Biochemistry an innovative method for a direct cytoplasmic detection of protein/protein interactions (CPPI).
September 2008,MilleGen is pleased to announce the successful evaluation by the Juvenile Diabetes Research Foundation (JDRF) to fund a research collaboration project between Copenhagen Univ. Stanford Univ., and MilleGen to engineer a biomarker, which targets insulin secreting functional human beta cells. Read the JDRF abstract.
August 2008, MilleGen is pleased to announce successful achievement of the final phase of a recombinant antibody library screening program for a FDA laboratory (Bethesda, MD,USA).
June 2008, MilleGen announces the successful evaluation by the "Pôle de compétitivité Cancer Bio Santé de Toulouse" of a project entitled "humanization of an antimetastatic murine monoclonal antibody". The project is in collaboration with a laboratory of INSERM in Lyon (France).
June 2008, MilleGen announces the successful achievement of the optimization of an industrial enzyme using its proprietary Mutagen™ technology published in Protein Science.
May 2008, MilleGen enters into collaborative agreement with Accuro to propose simultaneous humanisation, affinity and immunogenicity optimisation of monoclonal antibodies.
Read the complete press release
April 2008, MilleGen announces the publication of a Protein Engineering Design and Selection article on the complementarity diversity generated by its random mutagenesis technique MutaGen™.
March 2008, MilleGen is pleased to announce successful achievement of the first phase of a recombinant antibody library screening program for a FDA laboratory (Bethesda, MD,USA).
January 2008, MilleGen published a review entitled "Human antibody libraries: a race to engineer and explore a larger diversity" in Frontiers in Bioscience.
2007
October 2007, MilleGen is invited to give a presentation of its antibody discovery platform at Antibodies - Europe (November 7-8, 2007, Vienna, Austria).
Read the meeting report
September 2007,MilleGen launches a new method for a direct cytoplasmic detection of protein/protein interactions (Patent WO2007119165). This technology allows the characterization of proteins as well as partner identification, interaction mapping and drug discovery applications (screening small molecules, peptides or intrabodies able to modulate intracytoplasmic interactions).
August 2007, MilleGen reports the development of a robotic high-throughput screening platform published in Journal of Biomolecular Screening.
June 2007, MilleGen relocates its laboratories and head quarter into a new facility of 800 square meters in Labège (near Toulouse, France). This bigger facility will allow MilleGen to expand the automation and industrialization of its antibody and directed molecular evolution platform.
March 2007, Toulouse and les Ulis, FRANCE MilleGen and LFB sign research partnership agreement to develop new generation of therapeutic monoclonal antibodies.
Read complete press release
January 2007, MilleGen announces the development of a highly diverse human antibody library published in Biotechnology Journal.
